Picture of Akebia Therapeutics logo

AKBA Akebia Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

Akebia Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

* Akebia Therapeutics Inc  AKBA.OQ  reported a quarterly
adjusted
loss of 10 cents​​ per share for the quarter ended September 30,
lower than the same quarter last year, when the company reported
EPS of -8 cents.  The mean expectation of three analysts for the
quarter was for a loss of 6 cents per share. Wall Street
expected results to range from -9 cents to -3 cents per share.
    * Revenue fell 15.3% to $35.59 million from a year ago;
analysts
expected $44.51 million. 
    * Akebia Therapeutics Inc's reported EPS for the quarter was
a
loss of 10 cents​.
    * The company reported a quarterly loss of $20.04 million.
    * Akebia Therapeutics Inc shares had risen by 51.5% this
quarter and gained 61.3% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 24% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Akebia
Therapeutics Inc is 5.00 
This summary was machine generated from LSEG data November 7 at
02:15 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.06          -0.10          Missed
 Jun. 30 2024      -0.05          -0.04          Beat
 Mar. 31 2024      -0.08          -0.09          Missed
 Dec. 31 2023      -0.04          0.00           Beat

Recent news on Akebia Therapeutics

See all news